IGI Logo

Lupin is currently trading at Rs. 759.60, up by 10.40 points or 1.39% from its previous closing of Rs. 749.20 on the BSE.

The scrip opened at Rs. 755.80 and has touched a high and low of Rs. 762.00 and Rs. 750.00 respectively. So far 8737 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 971.30 on 13-Jan-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 762.00 and Rs. 730.00 respectively. The current market cap of the company is Rs. 34338.97 crore.

The promoters holding in the company stood at 47.11%, while Institutions and Non-Institutions held 41.44% and 11.45% respectively.

The Spanish Ministry of Health (MSCBC) has approved the reimbursement of Lupin’s NaMuscla (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders on the National Health and Pharmacy Service. NaMuscla is the first and only licensed product for this indication in Europe and will be commercialized by Lupin’s partner Exeltis in Spain.

NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain and is characterized by the inability to relax muscles following voluntary contraction (myotonia). NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients. NaMuscla, which has been designated orphan drug status, received EU marketing authorization in December 2018.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.